抑制GSK3β改善ARVC5小鼠模型的心功能与生存
本研究建立过表达TMEM43野生型或p.S358L突变体的转基因小鼠模型,发现突变小鼠重现人类ARVC5表型,表现为心肌细胞死亡、纤维脂肪替代及幼年死亡。TMEM43定位于核膜并与emerin和β-actin相互作用,突变体部分错位至胞质且激活GSK3β;过表达calcineurin Aβ1或使用GSK3β抑制剂可改善心功能并延长生存,患者iPSC来源细胞也显示GSK3β抑制可部分恢复收缩功能。
要点
- TMEM43-S358L突变导致心肌细胞死亡和纤维脂肪替代,小鼠幼年死亡。
- 突变体部分错位至胞质,与emerin和β-actin相互作用减弱,并激活GSK3β。
- GSK3β抑制可改善突变小鼠心功能并延长生存。
核心结论
- TMEM43-S358L导致持续心肌细胞死亡和纤维脂肪替代,抑制GSK3β可改善心功能并延长生存。
研究设计与样本
- 在α-肌球蛋白重链启动子控制下,于出生后心肌细胞过表达TMEM43野生型或p.S358L突变体的转基因小鼠模型。
- 此外使用携带p.S358L突变的人诱导多能干细胞。
主要发现
- 表达TMEM43-S358L的小鼠重现人类疾病并于幼年死亡。
- 突变TMEM43导致心肌细胞死亡和严重纤维脂肪替代。
- TMEM43定位于核膜并与emerin和β-actin相互作用。
- TMEM43-S358L部分错位至胞质,与emerin和β-actin相互作用减弱,并激活GSK3β。
- 靶向心脏纤维化无有益效果,而过表达calcineurin Aβ1导致GSK3β抑制并改善心功能和生存。
临床怎么用
- 对于ARVC5患者,GSK3β抑制可能成为新的治疗策略。
- 靶向心脏纤维化可能不是ARVC5的有效治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in heart failure and sudden cardiac death. The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (transmembrane protein 43). The function and localization of TMEM43 are unknown, as is the mechanism by which the p.S358L mutation causes the disease. Here, we report the characterization of the first transgenic mouse model of ARVC5. METHODS: We generated transgenic mice overexpressing TMEM43 in either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal cardiomyocytes under the control of the α-myosin heavy chain promoter. RESULTS: We found that mice expressing TMEM43-S358L recapitulate the human disease and die at a young age. Mutant TMEM43 causes cardiomyocyte death and severe fibrofatty replacement. We also demonstrate that TMEM43 localizes at the nuclear membrane and interacts with emerin and β-actin. TMEM43-S358L shows partial delocalization to the cytoplasm, reduced interaction with emerin and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). Furthermore, we show that targeting cardiac fibrosis has no beneficial effect, whereas overexpression of the calcineurin splice variant calcineurin Aβ1 results in GSK3β inhibition and improved cardiac function and survival. Similarly, treatment of TMEM43 mutant mice with a GSK3β inhibitor improves cardiac function. Finally, human induced pluripotent stem cells bearing the p.S358L mutation also showed contractile dysfunction that was partially restored after GSK3β inhibition. CONCLUSIONS: Our data provide evidence that TMEM43-S358L leads to sustained cardiomyocyte death and fibrofatty replacement. Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical GSK3β inhibition improves cardiac function and increases mice life span. Our results pave the way toward new therapeutic approaches for ARVC5.
引用
- Padrón-Barthe L, Villalba-Orero M, Gómez-Salinero JM, et al. Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β. Circulation. 2019. PMID: 31567019. doi:10.1161/CIRCULATIONAHA.119.040366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。